Biktarvy

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a prescription medication used to treat HIV-1 infection. A complete once-daily single-tablet regimen for treating HIV-1 infection in adults and many adolescents.

Combines an integrase inhibitor with two reverse-transcriptase inhibitors to block HIV from replicating.

Commonly reported side effects of Biktarvy include Worsening of hepatitis B after stopping, Headache, Diarrhea, Nausea, and Kidney problems. This is not a complete list — tell your doctor or pharmacist about any side effects you experience.

Yes. Biktarvy carries an FDA Boxed Warning — the agency's most serious safety warning. Read the full prescribing information and talk to your doctor about the risks before starting or changing treatment.

The active ingredient in Biktarvy is bictegravir/emtricitabine/tenofovir alafenamide, which belongs to a class of medicines known as Integrase Inhibitor + NRTI Combination.

Biktarvy is manufactured by Gilead Sciences. It was first approved in 2018.

You may be able to lower the cost of Biktarvy by using a free pharmacy discount card or by comparing prices across pharmacies before you fill your prescription. Savings vary by pharmacy and location.